IDH1 and central nervous system cancer: R132H-IDH1 inhibitor (AGI-5198) blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG), delayed growth and promoted differentiation of glioma cells (86).